Jasper Therapeutics (JSPR) analyst forecast and price target
Analyst forecast
Consensus of 4 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| William Blair | Maintained | Outperform | — | Oct 14, 2026 |
| Piper Sandler | Initiated Coverage | Overweight | $2.00 | Aug 12, 2026 |
| RBC Capital | Maintained | Sector Perform | $3.00 from $4.00 | May 15, 2026 |
| TD Cowen | Downgraded | Buy → Hold | — | May 15, 2026 |
| Evercore ISI Group | Maintained | Outperform | $7.00 from $12.00 | Apr 1, 2026 |
| UBS | Initiated Coverage | Neutral | $1.50 | Mar 23, 2026 |
| RBC Capital | Maintained | Sector Perform | $4.00 from $5.00 | Nov 11, 2025 |
| BTIG | Maintained | Buy | $7.00 from $20.00 | Sep 22, 2025 |
| Evercore ISI Group | Maintained | Outperform | $14.00 from $20.00 | Sep 22, 2025 |
| JMP Securities | Maintained | Market Outperform | $6.00 from $12.00 | Sep 22, 2025 |
| UBS | Maintained | Buy | $25.00 from $29.00 | Aug 15, 2025 |
| Evercore ISI Group | Maintained | Outperform | $20.00 from $50.00 | Jul 8, 2025 |
| JMP Securities | Maintained | Market Outperform | $12.00 from $70.00 | Jul 8, 2025 |
| BMO Capital | Downgraded | Outperform → Market Perform | $4.00 from $15.00 | Jul 8, 2025 |
| BTIG | Maintained | Buy | $20.00 from $64.00 | Jul 7, 2025 |
| Cantor Fitzgerald | Downgraded | Overweight → Neutral | — | Jul 7, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 from $40.00 | Jul 7, 2025 |
| William Blair | Downgraded | Outperform → Market Perform | — | Jul 7, 2025 |
| Oppenheimer | Maintained | Outperform | $65.00 from $80.00 | May 15, 2025 |
| UBS | Maintained | Buy | $33.00 from $38.00 | May 13, 2025 |
Frequently asked questions
Is JSPR a buy, sell, or hold?
Analysts covering Jasper Therapeutics currently average a Buy rating: 4 buy, 0 hold and 0 sell, from 4 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on JSPR?
On Oct 14, 2026, William Blair maintained Jasper Therapeutics at Outperform.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

